Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2025-11-10 00:00:00 ET · period of report 2025-11-06 · accession 0001610717-25-000372 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2025-11-10 | 2025-11-06 | CTMX | McCarthy Sean A. | CEO, Dir | S - Sale | $4.54 | -101.8K | 987.9K | -9% | -$462.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-11-06 | S | D | 101,793 | $4.54 | 987,891 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $4.50 to $4.62, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) Includes 488,750 restricted stock units. |